Allison Brashear

Title(s)Dean, Dean's Office
SchoolUniversity of California, Davis
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    7th Symposium on ATP1A3 function in health and disease
    NIH R13NS108697Aug 15, 2018 - Jun 30, 2019
    Role: Principal Investigator
    Wake Forest NeuroNext Clinical Site (WAKENN)
    NIH U24NS107197Jul 15, 2018 - Jun 30, 2023
    Role: Co-Principal Investigator
    NIH R01NS058949Apr 1, 2007 - Jun 30, 2026
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Rapid-onset dystonia-parkinsonism is associated with reduced cerebral blood flow without gray matter changes. Front Neurol. 2023; 14:1116723. Whitlow CT, Atcheson KM, Snively BM, Cook JF, Kim J, Haq IU, Sweadner KJ, Ozelius LJ, Brashear A. PMID: 36779071; PMCID: PMC9909223.
      View in: PubMed   Mentions:
    2. Temperature instability of a mutation at a multidomain junction in Na,K-ATPase isoform ATP1A3 (p.Arg756His) produces a fever-induced neurological syndrome. J Biol Chem. 2023 01; 299(1):102758. Arystarkhova E, Toustrup-Jensen MS, Holm R, Ko JK, Lee KE, Feschenko P, Ozelius LJ, Brashear A, Vilsen B, Sweadner KJ. PMID: 36462665; PMCID: PMC9860391.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    3. Aligning academic medicine within the healthcare system: the APS-SPR virtual chat series. Pediatr Res. 2022 Feb 11. Shanley T, Brashear A, Johnston SC. PMID: 35149847; PMCID: PMC8831878.
      View in: PubMed   Mentions: 1     Fields:    
    4. AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500�U/1�mL and 500�U/2�mL dilutions. Clin Park Relat Disord. 2021; 5:100115. Lew MF, Hauser RA, Isaacson SH, Truong D, Patel AT, Brashear A, Ondo W, Maisonobe P, Dashtipour K, Bahroo L, Wietek S. PMID: 34888518; PMCID: PMC8636802.
      View in: PubMed   Mentions:
    5. Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion. Eur J Neurol. 2021 12; 28(12):3999-4009. Wang M, Sajobi T, Morgante F, Adler C, Agarwal P, B?umer T, Berardelli A, Berman BD, Blumin J, Borsche M, Brashear A, Deik A, Duque K, Espay AJ, Ferrazzano G, Feuerstein J, Fox S, Frank S, Hallett M, Jankovic J, LeDoux MS, Leegwater-Kim J, Mahajan A, Malaty IA, Ondo W, Pantelyat A, Pirio-Richardson S, Roze E, Saunders-Pullman R, Suchowersky O, Truong D, Vidailhet M, Shukla AW, Perlmutter JS, Jinnah HA, Martino D. PMID: 34296504; PMCID: PMC9100858.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. A Multi-center Genome-wide Association Study of Cervical Dystonia. Mov Disord. 2021 12; 36(12):2795-2801. Sun YV, Li C, Hui Q, Huang Y, Barbano R, Rodriguez R, Malaty IA, Reich S, Bambarger K, Holmes K, Jankovic J, Patel NJ, Roze E, Vidailhet M, Berman BD, LeDoux MS, Espay AJ, Agarwal P, Pirio-Richardson S, Frank SA, Ondo WG, Saunders-Pullman R, Chouinard S, Natividad S, Berardelli A, Pantelyat AY, Brashear A, Fox SH, Kasten M, Kr?mer UM, Neis M, B?umer T, Loens S, Borsche M, Zittel S, Maurer A, Gelderblom M, Volkmann J, Odorfer T, K?hn AA, Borngr?ber F, K?nig IR, Cruchaga C, Cotton AC, Kilic-Berkmen G, Freeman A, Factor SA, Scorr L, Bremner JD, Vaccarino V, Quyyumi AA, Klein C, Perlmutter JS, Lohmann K, Jinnah HA. PMID: 34320236; PMCID: PMC8688173.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study. PLoS One. 2021; 16(4):e0250475. Patel AT, Lew MF, Dashtipour K, Isaacson S, Hauser RA, Ondo W, Maisonobe P, Wietek S, Rubin B, Brashear A. PMID: 33852647; PMCID: PMC8046252.
      View in: PubMed   Mentions:    Fields:    
    8. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study. J Rehabil Med. 2021 02 24; 53(2):jrm00157. Turner-Stokes L, Jacinto J, Fheodoroff K, Brashear A, Maisonobe P, Lysandropoulos A, Ashford S, Upper Limb International Spasticity (ULIS-III) study group. PMID: 33616192; PMCID: PMC8814868.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    9. Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study. PLoS One. 2021; 16(2):e0245827. Patel AT, Lew MF, Dashtipour K, Isaacson S, Hauser RA, Ondo W, Maisonobe P, Wietek S, Rubin B, Brashear A. PMID: 33524060; PMCID: PMC7850472.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    10. Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III Study. J Rehabil Med. 2021 Jan 01; 53(1):jrm00133. Turner-Stokes L, Jacinto J, Fheodoroff K, Brashear A, Maisonobe P, Lysandropoulos A, Ashford S, Upper Limb International Spasticity-III (ULIS-III) study group. PMID: 33206198; PMCID: PMC8772374.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    11. Misfolding, altered membrane distributions, and the unfolded protein response contribute to pathogenicity differences in Na,K-ATPase ATP1A3 mutations. J Biol Chem. 2021 Jan-Jun; 296:100019. Arystarkhova E, Ozelius LJ, Brashear A, Sweadner KJ. PMID: 33144327; PMCID: PMC7949067.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    12. Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA. Toxins (Basel). 2020 10 19; 12(10). Ayyoub Z, Brashear A, Banach M, Schoene R, Stringer W, Boodhoo T, Yushmanova I, Dimitrova R, Brin MF. PMID: 33086749; PMCID: PMC7589715.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort. Neurology. 2021 01 26; 96(4):e563-e574. Shaikh AG, Beylergil SB, Scorr L, Kilic-Berkmen G, Freeman A, Klein C, Junker J, Loens S, Br?ggemann N, M?nchau A, B?umer T, Vidailhet M, Roze E, Bonnet C, Jankovic J, Jimenez-Shahed J, Patel N, Marsh L, Comella C, Barbano RL, Berman BD, Malaty I, Wagle Shukla A, Reich SG, Ledoux MS, Berardelli A, Ferrazzano G, Stover N, Ondo W, Pirio Richardson S, Saunders-Pullman R, Mari Z, Agarwal P, Adler C, Chouinard S, Fox SH, Brashear A, Truong D, Suchowersky O, Frank S, Factor S, Perlmutter J, Jinnah HA. PMID: 33046615; PMCID: PMC7905789.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    14. Auditory-perceptual voice and speech evaluation in ATP1A3 positive patients. J Clin Neurosci. 2020 Nov; 81:133-138. Moya-Mendez ME, Madden LL, Ruckart KW, Downes KM, Cook JF, Snively BM, Brashear A, Haq IU. PMID: 33222902; PMCID: PMC7683823.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. The Effect of Repeated abobotulinumtoxinA (Dysport�) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury. PM R. 2021 05; 13(5):488-495. Esquenazi A, Brashear A, Deltombe T, Rudzinska-Bar M, Krawczyk M, Skoromets A, O'Dell MW, Grandoulier AS, Vilain C, Picaut P, Gracies JM. PMID: 32741133; PMCID: PMC8246752.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    16. Cardiac phenotype in ATP1A3-related syndromes: A multicenter cohort study. Neurology. 2020 11 24; 95(21):e2866-e2879. Balestrini S, Mikati MA, ?lvarez-Garc?a-Rov?s R, Carboni M, Hunanyan AS, Kherallah B, McLean M, Prange L, De Grandis E, Gagliardi A, Pisciotta L, Stagnaro M, Veneselli E, Campistol J, Fons C, Pias-Peleteiro L, Brashear A, Miller C, Sam?es R, Brankovic V, Padiath QS, Potic A, Pilch J, Vezyroglou A, Bye AME, Davis AM, Ryan MM, Semsarian C, Hollingsworth G, Scheffer IE, Granata T, Nardocci N, Ragona F, Arzimanoglou A, Panagiotakaki E, Carrilho I, Zucca C, Novy J, Dziezyc K, Parowicz M, Mazurkiewicz-Beldzinska M, Weckhuysen S, Pons R, Groppa S, Sinden DS, Pitt GS, Tinker A, Ashworth M, Michalak Z, Thom M, Cross JH, Vavassori R, Kaski JP, Sisodiya SM. PMID: 32913013; PMCID: PMC7734736.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    17. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Hemiparesis in Adults with Lower Limb Spasticity Previously Treated With Other Botulinum Toxins: A Secondary Analysis of a Randomized Controlled Trial. PM R. 2020 09; 12(9):853-860. Esquenazi A, Stoquart G, Hedera P, Jacinto LJ, Dimanico U, Constant-Boyer F, Brashear A, Grandoulier AS, Vilain C, Picaut P, Gracies JM. PMID: 32108436; PMCID: PMC7540573.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    18. IncobotulinumtoxinA Treatment in Upper-Limb Poststroke Spasticity in the Open-Label Extension Period of PURE: Efficacy in Passive Function, Caregiver Burden, and Quality of Life. PM R. 2020 05; 12(5):491-499. Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, Hanschmann A, Hiersemenzel R, Elovic EP. PMID: 31647185.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Saving neurology: Once more with feeling. Neurology. 2019 12 03; 93(23):989-990. Schor NF, Brashear A. PMID: 31690683.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Factors in the disease severity of ATP1A3 mutations: Impairment, misfolding, and allele competition. Neurobiol Dis. 2019 12; 132:104577. Arystarkhova E, Haq IU, Luebbert T, Mochel F, Saunders-Pullman R, Bressman SB, Feschenko P, Salazar C, Cook JF, Demarest S, Brashear A, Ozelius LJ, Sweadner KJ. PMID: 31425744; PMCID: PMC7397496.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    21. Revising rapid-onset dystonia-parkinsonism: Broadening indications for ATP1A3 testing. Mov Disord. 2019 10; 34(10):1528-1536. Haq IU, Snively BM, Sweadner KJ, Suerken CK, Cook JF, Ozelius LJ, Miller C, McCall WV, Whitlow CT, Brashear A. PMID: 31361359; PMCID: PMC6879786.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    22. Alternating Hemiplegia of Childhood in a Person of Malay Ethnicity with Diffusion Tensor Imaging Abnormalities. J Mov Disord. 2019 May; 12(2):132-134. Tan AH, Ong TL, Ramli N, Tan LK, Lim JL, Azhan MA, Ahmad-Annuar A, Ibrahim KA, Abdul-Aziz Z, Ozelius LJ, Brashear A, Lim SY. PMID: 31158946; PMCID: PMC6547042.
      View in: PubMed   Mentions: 1  
    23. Genotype-structure-phenotype relationships diverge in paralogs ATP1A1, ATP1A2, and ATP1A3. Neurol Genet. 2019 Feb; 5(1):e303. Sweadner KJ, Arystarkhova E, Penniston JT, Swoboda KJ, Brashear A, Ozelius LJ. PMID: 30842972; PMCID: PMC6384024.
      View in: PubMed   Mentions: 16  
    24. IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study. Adv Ther. 2019 01; 36(1):187-199. Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, Hanschmann A, Hiersemenzel R, Elovic EP. PMID: 30484117; PMCID: PMC6318229.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    25. Burnout in neurology: Extinguishing the embers and rekindling the joy in practice. Neurology. 2018 11 13; 91(20):907-908. Brashear A, Vickrey BG. PMID: 30305444.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    26. Gender bias in American Academy of Neurology recognition awards? Neurology. 2018 08 14; 91(7):291-292. Graves JS, Brashear A. PMID: 30030327.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study. Mov Disord Clin Pract. 2018 May-Jun; 5(3):273-282. Jankovic J, Truong D, Patel AT, Brashear A, Evatt M, Rubio RG, Oh CK, Snyder D, Shears G, Comella C. PMID: 30009213; PMCID: PMC6032882.
      View in: PubMed   Mentions: 16  
    28. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. Int J Neurosci. 2018 Jul; 128(7):619-626. Lew MF, Brashear A, Dashtipour K, Isaacson S, Hauser RA, Maisonobe P, Snyder D, Ondo W. PMID: 29343142.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    29. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension. Neurology. 2017 Nov 28; 89(22):2245-2253. Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P, International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group. PMID: 29093068; PMCID: PMC5705248.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    30. Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial. Toxins (Basel). 2017 07 11; 9(7). Devier D, Harnar J, Lopez L, Brashear A, Graham G. PMID: 28696373; PMCID: PMC5535163.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    31. Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study. PM R. 2018 01; 10(1):1-10. O'Dell MW, Brashear A, Jech R, Lejeune T, Marque P, Bensmail D, Ayyoub Z, Simpson DM, Volteau M, Vilain C, Picaut P, Gracies JM. PMID: 28634000.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    32. Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial. PM R. 2017 12; 9(12):1181-1190. Marciniak C, McAllister P, Walker H, Brashear A, Edgley S, Deltombe T, Khatkova S, Banach M, Gul F, Vilain C, Picaut P, Grandoulier AS, Gracies JM, International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group. PMID: 28625615.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    33. Head drop after botox: Electrodiagnostic evaluation of iatrogenic botulinum toxicity. Clin Neurol Neurosurg. 2017 May; 156:1-3. Szuch E, Caress JB, Paudyal B, Brashear A, Cartwright MS, Strowd RE. PMID: 28273554.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    34. Research conference summary from the 2014 International Task Force on ATP1A3-Related Disorders. Neurol Genet. 2017 Apr; 3(2):e139. Rosewich H, Sweney MT, DeBrosse S, Ess K, Ozelius L, Andermann E, Andermann F, Andrasco G, Belgrade A, Brashear A, Ciccodicola S, Egan L, George AL, Lewelt A, Magelby J, Merida M, Newcomb T, Platt V, Poncelin D, Reyna S, Sasaki M, Sotero de Menezes M, Sweadner K, Viollet L, Zupanc M, Silver K, Swoboda K. PMID: 28293679; PMCID: PMC5335249.
      View in: PubMed   Mentions: 24  
    35. Poster 289 Patient Registry of Spasticity Care World Data Analysis Based on Physician Experience. PM R. 2016 Sep; 8(9S):S254. Esquenazi A, Lee S, Mayer NH, Brashear A, Francisco GE, Yablon EE, Garreta R, Wissel J, Molteni F. PMID: 27673047.
      View in: PubMed   Mentions:    Fields:    
    36. Poster 288 Efficacy and Safety of Repeated AbobotulinumtoxinA Injections in Adults with Lower Limb Spasticity. PM R. 2016 Sep; 8(9S):S254. Gracies JM, Esquenazi A, Brashear A, Edgley SR, O'Dell M, Hedera P, Rubin BS, Picaut P. PMID: 27673046.
      View in: PubMed   Mentions: 1     Fields:    
    37. ATP1A3 Mutation in Adult Rapid-Onset Ataxia. PLoS One. 2016; 11(3):e0151429. Sweadner KJ, Toro C, Whitlow CT, Snively BM, Cook JF, Ozelius LJ, Markello TC, Brashear A. PMID: 26990090; PMCID: PMC4798776.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    38. A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin �1 subunit, Lamb1. Elife. 2015 Dec 24; 4. Liu YB, Tewari A, Salameh J, Arystarkhova E, Hampton TG, Brashear A, Ozelius LJ, Khodakhah K, Sweadner KJ. PMID: 26705335; PMCID: PMC4749547.
      View in: PubMed   Mentions: 9     Fields:    Translation:Animals
    39. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol. 2015 Oct; 14(10):992-1001. Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Marciniak C, Deltombe T, Skoromets A, Khatkova S, Edgley S, Gul F, Catus F, De Fer BB, Vilain C, Picaut P, International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group. PMID: 26318836.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    40. Novel mutations in ATP1A3 associated with catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly. Epilepsia. 2015 Mar; 56(3):422-30. Paciorkowski AR, McDaniel SS, Jansen LA, Tully H, Tuttle E, Ghoneim DH, Tupal S, Gunter SA, Vasta V, Zhang Q, Tran T, Liu YB, Ozelius LJ, Brashear A, Sweadner KJ, Dobyns WB, Hahn S. PMID: 25656163; PMCID: PMC4363281.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    41. Rapid-Onset Dystonia-Parkinsonism in a Chinese Girl with a De Novo ATP1A3 c.2267G>A (p.R756H) Genetic Mutation. Mov Disord Clin Pract. 2015 Mar; 2(1):74-75. Tan AH, Ozelius LJ, Brashear A, Lang AE, Ahmad-Annuar A, Tan CT, Lim SY. PMID: 30713883; PMCID: PMC6353356.
      View in: PubMed   Mentions: 3  
    42. Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings. Acta Neuropathol. 2014 Jul; 128(1):81-98. Oblak AL, Hagen MC, Sweadner KJ, Haq I, Whitlow CT, Maldjian JA, Epperson F, Cook JF, Stacy M, Murrell JR, Ozelius LJ, Brashear A, Ghetti B. PMID: 24803225; PMCID: PMC4059967.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    43. Distinct neurological disorders with ATP1A3 mutations. Lancet Neurol. 2014 May; 13(5):503-14. Heinzen EL, Arzimanoglou A, Brashear A, Clapcote SJ, Gurrieri F, Goldstein DB, J?hannesson SH, Mikati MA, Neville B, Nicole S, Ozelius LJ, Poulsen H, Schyns T, Sweadner KJ, van den Maagdenberg A, Vilsen B, ATP1A3 Working Group. PMID: 24739246; PMCID: PMC4238309.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansAnimals
    44. Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites. Mov Disord. 2014 May; 29(6):812-8. Saunders-Pullman R, Fuchs T, San Luciano M, Raymond D, Brashear A, Ortega R, Deik A, Ozelius LJ, Bressman SB. PMID: 24500857; PMCID: PMC4013240.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    45. Cognitive impairment in rapid-onset dystonia-parkinsonism. Mov Disord. 2014 Mar; 29(3):344-50. Cook JF, Hill DF, Snively BM, Boggs N, Suerken CK, Haq I, Stacy M, McCall WV, Ozelius LJ, Sweadner KJ, Brashear A. PMID: 24436111; PMCID: PMC3960305.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    46. ATP1A3 mutations: what is the phenotype? Neurology. 2014 Feb 11; 82(6):468-9. Brashear A, Ozelius LJ, Sweadner KJ. PMID: 24431297.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    47. Commentary. Mov Disord. 2013 Dec; 28(14):1939. Brashear A. PMID: 24323532.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    48. Coding for the use of botulinum toxin for movement disorders. Continuum (Minneap Minn). 2013 Oct; 19(5 Movement Disorders):1406-15. Brashear A, Bushong L. PMID: 24092297.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Treatment of cervical dystonia. Expert Opinion on Orphan Drugs. 2013 Oct 1; 1(8):599-606. Brashear BA. .
      View in: Publisher Site   Mentions:
    50. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(�)) in cervical dystonia. J Neural Transm (Vienna). 2013 Dec; 120(12):1699-707. Evidente VG, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL. PMID: 23779062; PMCID: PMC3834167.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    51. Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland. Eur J Neurol. 2013 May; 20(5):773-80. Doan QV, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, Lu ZJ. PMID: 23278954.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    52. Patient registry of outcomes in spasticity care. Am J Phys Med Rehabil. 2012 Sep; 91(9):729-46. Esquenazi A, Mayer N, Lee S, Brashear A, Elovic E, Francisco GE, Yablon S, PROS Study Group. PMID: 22469872.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    53. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012 Sep-Oct; 35(5):208-14. Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF, CD 140 Study Group. PMID: 22948497.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    54. Psychiatric disorders in rapid-onset dystonia-parkinsonism. Neurology. 2012 Sep 11; 79(11):1168-73. Brashear A, Cook JF, Hill DF, Amponsah A, Snively BM, Light L, Boggs N, Suerken CK, Stacy M, Ozelius L, Sweadner KJ, McCall WV. PMID: 22933743; PMCID: PMC3525305.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    55. ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia. Dev Med Child Neurol. 2012 Nov; 54(11):1065-7. Brashear A, Mink JW, Hill DF, Boggs N, McCall WV, Stacy MA, Snively B, Light LS, Sweadner KJ, Ozelius LJ, Morrison L. PMID: 22924536; PMCID: PMC3465467.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    56. New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism. Parkinsonism Relat Disord. 2012 Jul; 18(6):737-41. Barbano RL, Hill DF, Snively BM, Light LS, Boggs N, McCall WV, Stacy M, Ozelius L, Sweadner KJ, Brashear A. PMID: 22534615; PMCID: PMC3753404.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    57. Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. PM R. 2012 Jan; 4(1):4-10. Doan QV, Brashear A, Gillard PJ, Varon SF, Vandenburgh AM, Turkel CC, Elovic EP. PMID: 22200567.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    58. Comment: The new mentoring and team leadership. Neurology. 2011 Aug 16; 77(7):685. Brashear A. PMID: 21795648.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. A diagnostic test to distinguish psychogenic dystonia from organic dystonia? Neurology. 2011 Feb 15; 76(7):590-1. Chen R, Brashear A. PMID: 21321331.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    60. Botulinum toxin type A: Exploring new indications. Drugs Today (Barc). 2010 Sep; 46(9):671-82. Brashear A. PMID: 20967299.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    61. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23. Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S, Global Dysport Cervical Dystonia Study Group. PMID: 20359934.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    62. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics. 2009; 3:1-7. Brashear A. PMID: 19707390; PMCID: PMC2726049.
      View in: PubMed   Mentions: 10  
    63. Spasticity. Curr Treat Options Neurol. 2009 May; 11(3):153-61. Brashear A, Lambeth K. PMID: 19364449.
      View in: PubMed   Mentions: 3  
    64. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009 Apr; 80(4):380-5. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A, BoNT/TZD Study Team. PMID: 18977811.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    65. Clinical comparisons of botulinum neurotoxin formulations. Neurologist. 2008 Sep; 14(5):289-98. Brashear A. PMID: 18784598.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    66. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M, CD-017 BoNTA Study Group. PMID: 18546321.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCTClinical Trials
    67. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 06; 70(19):1699-706. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. PMID: 18458230; PMCID: PMC5565261.
      View in: PubMed   Mentions: 131     Fields:    Translation:Humans
    68. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008 May; 89(5):799-806. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C. PMID: 18452724.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    69. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007 Apr; 29(4):683-90. Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, Liu J, Brin MF. PMID: 17617291.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    70. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain. 2007 Mar; 130(Pt 3):828-35. Brashear A, Dobyns WB, de Carvalho Aguiar P, Borg M, Frijns CJ, Gollamudi S, Green A, Guimaraes J, Haake BC, Klein C, Linazasoro G, Münchau A, Raymond D, Riley D, Saunders-Pullman R, Tijssen MA, Webb D, Zaremba J, Bressman SB, Ozelius LJ. PMID: 17282997.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    71. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. PMID: 17190952.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    72. The safety and tolerability of botulinum toxins for the treatment of cervical dystonia. Expert Opin Drug Saf. 2005 Mar; 4(2):241-9. Brashear A. PMID: 15794717.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    73. Chapter L1 Spasticity. . 2005 Jan 1; (Arch Phys Med Rehab7511994):679-686. Brashear BA. .
      View in: Publisher Site   Mentions:
    74. Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia. Adv Ther. 2005 Jan-Feb; 22(1):49-55. Brashear A, Hogan P, Wooten-Watts M, Marchetti A, Magar R, Martin J. PMID: 15943222.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    75. Rapid-onset dystonia-parkinsonism: a fourth family consistent with linkage to chromosome 19q13. Mov Disord. 2004 Dec; 19(12):1506-10. Zaremba J, Mierzewska H, Lysiak Z, Kramer P, Ozelius LJ, Brashear A. PMID: 15390049.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    76. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr Res. 2004 Dec 01; 71(2-3):371-5. Yoder KK, Hutchins GD, Morris ED, Brashear A, Wang C, Shekhar A. PMID: 15474908.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    77. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology. 2004 Nov 23; 63(10):1971-3. Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, Turkel C, BOTOX Poststroke Spasticity Study Group. PMID: 15557529.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    78. Mutations in the Na+/K+ -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron. 2004 Jul 22; 43(2):169-75. de Carvalho Aguiar P, Sweadner KJ, Penniston JT, Zaremba J, Liu L, Caton M, Linazasoro G, Borg M, Tijssen MA, Bressman SB, Dobyns WB, Brashear A, Ozelius LJ. PMID: 15260953.
      View in: PubMed   Mentions: 183     Fields:    Translation:HumansCells
    79. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004 Jul; 85(7):1063-9. Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, Walcott JM, Jenkins SW, Turkel C, Molloy PT. PMID: 15241751.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    80. Refined linkage to the RDP/DYT12 locus on 19q13.2 and evaluation of GRIK5 as a candidate gene. Mov Disord. 2004 Jul; 19(7):845-847. Kamm C, Leung J, Joseph S, Dobyns WB, Brashear A, Breakefield XO, Ozelius LJ. PMID: 15254951.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    81. Treatment of cervical dystonia with botulinum toxin. Operative Techniques in Otolaryngology-Head and Neck Surgery. 2004 Jun 1; 15(2):122-127. Brashear BA. .
      View in: Publisher Site   Mentions:
    82. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2004 May; 85(5):705-9. Brashear A, McAfee AL, Kuhn ER, Fyffe J. PMID: 15129392.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    83. Use of botulinum toxin type A in poststroke spasticity. Expert Rev Neurother. 2003 May; 3(3):271-7. Brashear A. PMID: 19810893.
      View in: PubMed   Mentions:    Fields:    
    84. Botulinum toxin for spasticity after stroke. N Engl J Med. 2003 Jan 16; 348(3):258-9; author reply 258-9. Dobkin BH. PMID: 12530439.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil. 2003 Jan; 84(1):103-7. Brashear A, McAfee AL, Kuhn ER, Ambrosius WT. PMID: 12589629.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    86. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil. 2002 Oct; 83(10):1349-54. Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez N, Gracies JM, Gordon MF, McAfee A, Ruffing K, Thompson B, Williams M, Lee CH, Turkel C. PMID: 12370866.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    87. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002 Aug 08; 347(6):395-400. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C, Botox Post-Stroke Spasticity Study Group. PMID: 12167681.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCTClinical Trials
    88. Botulinum toxin type B: a new injectable treatment for cervical dystonia. Expert Opin Investig Drugs. 2001 Dec; 10(12):2191-9. Brashear A. PMID: 11772315.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    89. Cervical dystonia severity scale reliability study. Mov Disord. 2001 Nov; 16(6):1086-90. O'Brien C, Brashear A, Cullis P, Truong D, Molho E, Jenkins S, Wojcieszek J, O'Neil T, Factor S, Seeberger L. PMID: 11748739.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    90. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics. 2001 Nov; 108(5):1062-71. Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, Garcia de Yebenes Prous J, Smith BP, Turkel C, Walcott JM, Molloy PT. PMID: 11694682.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    91. The botulinum toxins in the treatment of cervical dystonia. Semin Neurol. 2001; 21(1):85-90. Brashear A. PMID: 11346029.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    92. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther. 2000 Dec; 22(12):1516-24. Brashear A, Watts MW, Marchetti A, Magar R, Lau H, Wang L. PMID: 11192142.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    93. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord. 2000 Jan; 15(1):150-3. Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W. PMID: 10634256.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    94. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000; 55(12 Suppl 5):S29-35. Lew MF, Brashear A, Factor S. PMID: 11188982.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    95. Metrifonate treatment of AD: influence of APOE genotype. Neurology. 1999 Dec 10; 53(9):2010-6. Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B. PMID: 10599773.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    96. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999 Oct 22; 53(7):1439-46. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. PMID: 10534248.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    97. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13. Ann Neurol. 1999 Aug; 46(2):176-82. Kramer PL, Mineta M, Klein C, Schilling K, de Leon D, Farlow MR, Breakefield XO, Bressman SB, Dobyns WB, Ozelius LJ, Brashear A. PMID: 10443882.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    98. Rapid onset dystonia-parkinsonism in a 14-year-old girl. Eur J Paediatr Neurol. 1999; 3(4):171-3. Webb DW, Broderick A, Brashear A, Dobyns WB. PMID: 10476366.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    99. PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP). Mov Disord. 1999 Jan; 14(1):132-7. Brashear A, Mulholland GK, Zheng QH, Farlow MR, Siemers ER, Hutchins GD. PMID: 9918356.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    100. Impaired traffic sign recognition in drivers with dementia. American Journal of Alzheimer's Disease & Other Dementias®. 1998 May 1; 13(3):131-137. Brashear BA, Unverzagt UF, Kuhn KE, Glazier GB, Farlow FM, Perkins PA, Hui HS. .
      View in: Publisher Site   Mentions:
    101. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism. Ann Neurol. 1998 Apr; 43(4):521-6. Brashear A, Butler IJ, Hyland K, Farlow MR, Dobyns WB. PMID: 9546335.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    102. Rapid-onset dystonia-parkinsonism: a report of clinical, biochemical, and genetic studies in two families. Adv Neurol. 1998; 78:335-9. Brashear A, Butler IJ, Ozelius LJ, Kramer PI, Farlow MR, Breakefield XO, Dobyns WB. PMID: 9750930.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    103. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord. 1998 Jan; 13(1):158-61. Brashear A, Ambrosius WT, Eckert GJ, Siemers ER. PMID: 9452343.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    104. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics. 1997 Dec; 12(6):695-706. Dodel RC, Kirchner A, Koehne-Volland R, Künig G, Ceballos-Baumann A, Naumann M, Brashear A, Richter HP, Szucs TD, Oertel WH. PMID: 10175981.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    105. Focal dystonia after chemotherapy: a case series. J Neurooncol. 1997 Sep; 34(2):163-7. Brashear A, Siemers E. PMID: 9210064.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    106. Rapid-onset dystonia-parkinsonism in a second family. Neurology. 1997 Apr; 48(4):1066-9. Brashear A, DeLeon D, Bressman SB, Thyagarajan D, Farlow MR, Dobyns WB. PMID: 9109901.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    107. Ethylene oxide neurotoxicity: a cluster of 12 nurses with peripheral and central nervous system toxicity. Neurology. 1996 Apr; 46(4):992-8. Brashear A, Unverzagt FW, Farber MO, Bonnin JM, Garcia JG, Grober E. PMID: 8780078.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    108. Variable phenotype of rapid-onset dystonia-parkinsonism. Mov Disord. 1996 Mar; 11(2):151-6. Brashear A, Farlow MR, Butler IJ, Kasarskis EJ, Dobyns WB. PMID: 8684384.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    109. The influence of the reference electrode on CMAP configuration: leg nerve observations and an alternative reference site. Muscle Nerve. 1996 Jan; 19(1):63-7. Brashear A, Kincaid JC. PMID: 8538671.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    110. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry. 1995 Oct; 152(10):1485-92. Hendrie HC, Osuntokun BO, Hall KS, Ogunniyi AO, Hui SL, Unverzagt FW, Gureje O, Rodenberg CA, Baiyewu O, Musick BS. PMID: 7573588.
      View in: PubMed   Mentions: 115     Fields:    Translation:Humans
    111. Percutaneous celiac plexus block with botulinum toxin A did not help the pain of chronic pancreatitis. J Clin Gastroenterol. 1995 Jun; 20(4):343-4. Sherman S, Kopecky KK, Brashear A, Lehman GA. PMID: 7665834.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    112. Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Ann Neurol. 1995 Jan; 37(1):118-20. Hendrie HC, Hall KS, Hui S, Unverzagt FW, Yu CE, Lahiri DK, Sahota A, Farlow M, Musick B, Class CA, et al. PMID: 7818244.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    113. Cross-national interrater agreement on the clinical diagnostic criteria for dementia. WHO-PRA Age-Associated Dementia Working Group, WHO-Program for Research on Aging, Health of Elderly Program. Neurology. 1994 Feb; 44(2):239-42. Baldereschi M, Amato MP, Nencini P, Pracucci G, Lippi A, Amaducci L, Gauthier S, Beatty L, Quiroga P, Klassen G, et al. PMID: 8309565.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    114. Rapid-onset dystonia-parkinsonism. Neurology. 1993 Dec; 43(12):2596-602. Dobyns WB, Ozelius LJ, Kramer PL, Brashear A, Farlow MR, Perry TR, Walsh LE, Kasarskis EJ, Butler IJ, Breakefield XO. PMID: 8255463.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    115. The influence of the reference electrode on CMAP configuration. Muscle Nerve. 1993 Apr; 16(4):392-6. Kincaid JC, Brashear A, Markand ON. PMID: 8455652.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    116. Takayasu's Arteritis and Multiple Sclerosis. Journal of Neuroimaging. 1992 Jan 1; 2(1):36-38. Brashear BA, Pascuzzi PR. .
      View in: Publisher Site   Mentions:
    117. The ventilatory response to intravenous and ventriculo-cisternal theophylline. Res Commun Chem Pathol Pharmacol. 1983 Jul; 41(1):79-94. Wick JE, DeAtley RE, Oei TO, Glick MR, Brashear A, Baenziger J, Brashear RE. PMID: 6622832.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    118. A spectrophotometric, enzymatic assay for D-3-hydroxybutyrate that is not dependent on hydrazine. Anal Biochem. 1983 Jun; 131(2):478-82. Brashear A, Cook GA. PMID: 6614481.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    Allison's Networks
    Concepts (373)
    Derived automatically from this person's publications.
    Co-Authors (5)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department